# Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

> **NCT04317534** · PHASE2 · RECRUITING · sponsor: **Greg Durm, MD** · enrollment: 244 (estimated)

## Conditions studied

- NSCLC, Stage I

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04317534
- **Lead sponsor:** Greg Durm, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-05
- **Primary completion:** 2027-04-08
- **Final completion:** 2028-04-08
- **Target enrollment:** 244 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04317534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04317534, "Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04317534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*